Short answer
Absci Corp (ABSI) filed an 8-K current report with the SEC on June 24, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). $100.0 million gross equity offering: 13,495,277 shares at $7.41 each.
Absci Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $100.0 million gross equity offering: 13,495,277 shares at $7.41 each
- Approximately $93.5 million net proceeds after underwriting discounts and expenses
- Significant shareholder dilution from newly issued common stock
- Proceeds targeted toward ABS-201 development in pattern hair loss and endometriosis
- Closing expected June 25, 2026; remaining funds for working capital and general corporate purposes
Item 8.01 · Other Events
- June 24, 2026 press release announced pricing of Absci’s offering
- Offering terms and potential financing impact are contained in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- $100 million gross equity financing through 13,495,277 shares priced at $7.41 each
- Dilution from newly issued shares, with underwriting discounts and offering expenses reducing net proceeds
- Proceeds earmarked for ABS-201 advancement in androgenetic alopecia and endometriosis
- Eli Lilly and institutional investors Adage, BVF Partners, Columbia Threadneedle, Invus, and Redmile participating
- Closing expected June 25, 2026, subject to customary conditions
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Absci Corp 8-K filings
Get the next ABSI 8-K as it lands
Follow ABSI for push alerts, or ask the research agent what this filing means.